MNKD Mannkind Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: MNKD

Price (delayed)

$3.59

Market cap

$967.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.12

Enterprise value

$1.27B

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its ...

Highlights
The revenue has soared by 132% YoY and by 12% from the previous quarter
Mannkind's gross margin has surged by 113% YoY and by 10% QoQ
The equity has declined by 6% year-on-year but it has increased by 3.3% since the previous quarter
Mannkind's quick ratio has decreased by 47% YoY and by 5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.mannkindcorp.com/
Peers: HALO LLY MRK PFE

Key stats

What are the main financial stats of MNKD
Market
Shares outstanding
269.57M
Market cap
$967.77M
Enterprise value
$1.27B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.46
EV/EBIT
N/A
EV/EBITDA
26,944.79
EV/Sales
7.17
Earnings
Revenue
$176.55M
EBIT
-$6.19M
EBITDA
$47,000
Free cash flow
-$31.62M
Per share
EPS
-$0.12
Free cash flow per share
-$0.12
Book value per share
-$0.94
Revenue per share
$0.66
TBVPS
$1.18
Balance sheet
Total assets
$320.33M
Total liabilities
$572.11M
Debt
$381.65M
Equity
-$251.78M
Working capital
$129.2M
Liquidity
Debt to equity
-1.52
Current ratio
2.34
Quick ratio
1.69
Net debt/EBITDA
6,353.87
Margins
EBITDA margin
0%
Gross margin
65.5%
Net margin
-17.7%
Operating margin
-5.3%
Efficiency
Return on assets
-10.2%
Return on equity
N/A
Return on invested capital
-1.2%
Return on capital employed
-2.8%
Return on sales
-3.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MNKD stock price

How has the Mannkind stock price performed over time
Intraday
-3.23%
1 week
1.41%
1 month
-2.45%
1 year
-21.44%
YTD
-31.88%
QTD
-13.08%

Financial performance

How have Mannkind's revenue and profit performed over time
Revenue
$176.55M
Gross profit
$115.72M
Operating income
-$9.36M
Net income
-$31.29M
Gross margin
65.5%
Net margin
-17.7%
The revenue has soared by 132% YoY and by 12% from the previous quarter
Mannkind's gross margin has surged by 113% YoY and by 10% QoQ
MNKD's operating margin has surged by 95% year-on-year and by 65% since the previous quarter
MNKD's operating income has soared by 89% YoY and by 61% QoQ

Growth

What is Mannkind's growth rate over time

Valuation

What is Mannkind stock price valuation
P/E
N/A
P/B
N/A
P/S
5.46
EV/EBIT
N/A
EV/EBITDA
26,944.79
EV/Sales
7.17
Mannkind's EPS has soared by 68% YoY and by 37% from the previous quarter
The equity has declined by 6% year-on-year but it has increased by 3.3% since the previous quarter
The revenue has soared by 132% YoY and by 12% from the previous quarter
The P/S is 42% lower than the 5-year quarterly average of 9.4 and 38% lower than the last 4 quarters average of 8.8

Efficiency

How efficient is Mannkind business performance
Mannkind's ROS has soared by 96% YoY and by 75% from the previous quarter
The company's return on invested capital has surged by 91% YoY and by 71% QoQ
The ROA has soared by 68% YoY and by 35% QoQ

Dividends

What is MNKD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNKD.

Financial health

How did Mannkind financials performed over time
The company's total assets is 44% lower than its total liabilities
Mannkind's quick ratio has decreased by 47% YoY and by 5% QoQ
The company's current ratio fell by 36% YoY
The equity has declined by 6% year-on-year but it has increased by 3.3% since the previous quarter
The debt to equity is up by 6% year-on-year but it is down by 3.4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.